Cumberland Pharmaceuticals Inc. CPIX PHARMA
Company Overview
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.28.
Recent Developments
- Dec 2025 Revenue of $44.52M (+17.6% YoY); net profit $-2.84M.
- Trailing 12 Months Year-on-year growth — revenue -56.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.14% |
| 1 Year: | -56.30% |
Stock Price Performance
| 1 Year: | +191.36% |
| 6 Months: | +150.35% |
| 3 Months: | +45.68% |
| 1 Month: | -15.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)43.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 26.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CPIX Cumberland Pharmaceuticals Inc. PHARMA | 6.62 | -30.09 | $99.19M | 0.00% | -6.97% | -14.39% | 0.14% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 11.20M | - | 8.59M | 10.16M | 8.49M | - | 8.73M | 9.42M | 6.94M | - | 8.33M | 9.60M | 9.25M | - | 10.54M | 9.06M | 8.07M | - | 11.18M | 10.30M | 11.41M | 9.12M | 9.22M | 10.89M | 10.09M | 9.35M | 8.50M | 9.85M | 9.09M | 10.44M | 11.71M | 10.84M | 8.29M | 13.68M | 9.13M |
| Operating Income | -105.31K | 130.13K | -957.37K | -657.80K | -1.68M | -839.35K | -903.33K | -2.45M | -868.98K | -1.81M | -2.26M | -1.32M | -1.37M | -3.20M | -3.39M | -1.85M | -1.58M | -1.21M | -1.75M | -324.30K | -1.44M | -1.56M | -4.35M | -1.29M | -1.85M | -288.59K | -2.28M | -1.53M | 22.86K | -1.87M | -6.18M | -1.87M | -1.03M | -1.69M | -1.84M | 1.29M | -747.48K | -1.97M | -1.37M | -3.13M |
| Net Income | -48.04K | 106.17K | -749.69K | -1.27M | -5.16M | -743.03K | -800.54K | -2.38M | -720.69K | -1.64M | -2.22M | -73.88K | -549.51K | -1.95M | -960.71K | -1.06M | -918.27K | -481.74K | -883.78K | 166.83K | 1.23M | -1.06M | -3.85M | -1.39M | -1.34M | -408.64K | -2.44M | 192.18K | 872.20K | -1.05M | -6.29M | -1.95M | -1.09M | -1.54M | -1.90M | 1.26M | -740.74K | -1.94M | -1.41M | -3.29M |
| Diluted EPS | 0.00 | 0.01 | -0.05 | -0.08 | -0.32 | -0.05 | -0.05 | -0.15 | -0.05 | -0.11 | -0.14 | 0.00 | -0.04 | -0.13 | -0.06 | -0.07 | -0.06 | -0.03 | -0.06 | 0.01 | 0.08 | -0.07 | -0.26 | -0.09 | -0.09 | -0.03 | -0.17 | 0.01 | 0.06 | -0.07 | -0.44 | -0.14 | -0.08 | -0.11 | -0.14 | 0.08 | -0.05 | -0.13 | -0.09 | -0.22 |
| R&D Expense | 678.78K | 644.66K | - | 898.36K | 1.08M | 943.16K | - | 1.87M | 1.45M | 1.31M | - | 1.40M | 1.72M | 1.67M | - | 1.72M | 1.42M | 1.23M | - | 1.26M | 1.36M | 1.45M | - | 1.75M | 1.82M | 1.71M | - | 1.50M | 1.15M | 1.92M | - | 1.16M | 1.06M | 1.31M | - | 1.30M | 1.47M | 1.25M | - | 1.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.54M | 45.88M | 51.14M | 700.00K | 800.00K | 600.00K | 900.00K | 32.48M | 40.38M | 28.80M | 32.41M | 35.84M | 35.05M | 42.01M | 39.55M | 37.87M | 44.52M |
| Operating Income | 5.78M | 6.50M | 9.85M | 8.82M | -3.80M | 3.56M | 1.11M | -1.43M | -4.08M | -11.17M | -9.29M | -6.38M | -7.68M | -5.70M | -9.55M | -6.43M | -2.79M |
| Net Income | 3.09M | 2.46M | 5.66M | 5.84M | -2.10M | 2.42M | 731.35K | -944.68K | -7.98M | -6.96M | -3.54M | -3.34M | -3.51M | -5.57M | -6.28M | -6.48M | -2.84M |
| Diluted EPS | 0.17 | 0.12 | 0.28 | 0.30 | -0.11 | 0.14 | 0.04 | -0.06 | -0.50 | -0.45 | -0.23 | -0.22 | -0.24 | -0.38 | -0.44 | -0.46 | -0.19 |
| R&D Expense | 4.99M | 4.33M | 5.03M | 5.10M | 5.62M | 3.39M | 3.85M | 3.19M | 4.28M | 7.58M | 6.87M | 5.77M | 5.68M | 6.69M | 5.83M | 4.82M | 5.57M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 92.05M | 95.52M | 98.59M | 87.61M | 95.41M | 91.92M | 93.40M | 93.23M | 112.69M | 104.55M | 96.46M | 84.46M | 92.93M | 81.78M | 75.58M | 76.82M |
| Total Equity | - | 72.22M | 77.78M | 82.93M | 85.70M | 79.47M | 80.76M | 76.89M | 73.25M | 64.12M | 55.84M | 51.12M | 46.99M | 42.81M | 36.27M | 29.60M | 22.85M | 24.88M |
| Cash & Equivalents | 11.83M | 78.70M | 65.89M | 70.60M | 54.35M | 40.87M | 39.87M | 38.20M | 34.51M | 45.41M | 27.94M | 28.21M | 24.75M | 27.04M | 19.76M | 18.32M | 17.96M | 11.44M |
| Total Liabilities | - | - | 14.34M | 12.68M | 13.03M | 8.32M | 14.65M | 15.10M | 20.28M | 29.31M | 57.12M | 53.46M | 49.59M | 41.86M | 56.95M | 52.52M | 53.04M | 52.28M |
| Current Liabilities | - | - | 9.23M | 6.60M | 8.06M | 7.55M | 13.75M | 12.41M | 14.79M | 17.69M | 27.80M | 24.15M | 25.67M | 19.28M | 28.58M | 27.98M | 31.62M | 36.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 404.97K | 346.66K | 8.72M | 7.14M | 746.13K | 6.69M | 5.88M | 569.48K | -557.71K | 3.11M | 3.06M | 5.42M | 6.34M | 8.45M | 6.09M | -612.19K | 4.93M |
| Investing Cash Flow | -712.34K | -768.64K | -437.77K | -19.18M | -5.07M | -6.03M | -2.34M | -3.12M | 9.51M | -27.72M | 2.30M | -1.76M | -501.89K | -13.67M | -105.69K | 57.84K | -4.71M |
| Financing Cash Flow | 67.18M | -12.39M | -3.58M | -4.21M | -9.15M | -1.66M | -5.19M | -1.15M | 1.95M | 7.14M | -5.08M | -7.12M | -3.55M | -2.06M | -7.42M | 196.90K | -6.75M |
| Capital Expenditure | -601.80K | -577.16K | -257.50K | -464.89K | -97.41K | -163.26K | -142.97K | -130.87K | -275.96K | -455.57K | -246.20K | -140.82K | -103.53K | -102.15K | -281.27K | -66.46K | -97.90K |
| Free Cash Flow | -196.83K | -230.50K | 8.46M | 6.67M | 648.71K | 6.53M | 5.73M | 438.61K | -833.67K | 2.66M | 2.81M | 5.27M | 6.24M | 8.35M | 5.81M | -678.65K | 4.83M |
| Share Buybacks | 27.30M | 4.85M | 4.25M | 8.09M | 4.80M | 4.32M | 5.34M | 2.52M | 3.72M | 2.88M | 3.49M | 1.85M | 1.39M | 1.05M | 740.53K | 579.05K | 263.48K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 13.3% | 14.2% | 19.3% | 1,259.7% | -475.2% | 593.1% | 123.5% | -4.4% | -10.1% | -38.8% | -28.7% | -17.8% | -21.9% | -13.6% | -24.2% | -17.0% | -6.3% |
| Net Margin % | 7.1% | 5.4% | 11.1% | 834.6% | -263.1% | 404.0% | 81.3% | -2.9% | -19.8% | -24.2% | -10.9% | -9.3% | -10.0% | -13.3% | -15.9% | -17.1% | -6.4% |
| ROE % | 4.3% | 3.2% | 6.8% | 6.8% | -2.6% | 3.0% | 1.0% | -1.3% | -12.4% | -12.5% | -6.9% | -7.1% | -8.2% | -15.4% | -21.2% | -28.4% | -11.4% |
| ROCE % | - | 7.8% | 11.1% | 9.7% | -4.7% | 4.4% | 1.4% | -1.8% | -5.4% | -13.2% | -11.6% | -9.0% | -11.8% | -8.9% | -17.8% | -14.6% | -7.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 3.36% | 503.15K | $3.68M |
| 2 | Renaissance Technologies, LLC | 3.19% | 478.26K | $3.50M |
| 3 | Vanguard Capital Management LLC | 2.53% | 379.48K | $2.78M |
| 4 | Dimensional Fund Advisors LP | 1.56% | 233.31K | $1.71M |
| 5 | Boothbay Fund Management, LLC | 0.75% | 112.54K | $823.82K |
| 6 | Geode Capital Management, LLC | 0.72% | 108.41K | $793.58K |
| 7 | Perceptive Advisors Llc | 0.65% | 96.98K | $709.91K |
| 8 | Citadel Advisors Llc | 0.49% | 73.39K | $537.22K |
| 9 | Blackrock Inc. | 0.42% | 63.55K | $465.16K |
| 10 | Bank Of New York Mellon Corporation | 0.39% | 58.46K | $427.91K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CPIX
Understanding Momentum Shifts in (CPIX) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQV2NtMFE3RGxNMGdTeC1nVlZMbk9jcjcxeG1jc2V0bGIzYk9sY0FqTVBkbXc3YmlCcGhjQUNYbjJPajEzQ2pKTVFOVHVqWnlCZFE0TllUbWNrNlVHVnFhMUNHbGhyQzVBQWk5MTZXYmVzQ2M3MkpmSDlabDZCc000WVFRTnVQUENvQ3pLRU…
Cumberland takes $100M cash deal, keeps three Phase II programs - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOYVIybS1UZWtLYlpUbEtlZGhrQnhGVzJSdnVUU29kYnZuZ1pCRjlvTzZHUGtTZERNRzJZSFZKSEcycklHZGpVaDBVQm9IZndIbDVOOG9HWFBwejVfMHpULUZzdmxuTHY0a3dvTFc1dWR1VVhyM2tIRmpnNF9wLWotdXozcU1ZNkg0dFllZk…
Cumberland Pharmaceuticals (CPIX) Stock Cools As Cash Rich Biotech Pivot Begins - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNS1h6UnFKaEFuR1hyNERXRWJZY0NMcDdUbFNYSExZQXQ1QUc5VHU0QkxCdWFVY0lFX1ZLMENlSmY2cUEtV3dCZG1nVmxHUWdWVnZ6MHhyNlVpWlZ4cW10dDJTVEtCMnAxWUF3dllPaDZpaVF1SHQyMlMyem4wNmNqbG5scVpGb3pNRG1VRm…
Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average - Time to Sell? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxOYzZFc1NaTUU1WEFhUXhTTi1MUm5ab0s4V0RMZGI5TXNTMm1uTUlacVdKMTdNN21KZjYyYkdDc2JhbWtIcmVMUDF5SVB5SE1FVmJQRTY1eDdmN3Bub29EVGtsMXZvVm9NVlk2WnNuQnFIUW9OMThwalZldmNoLXhoaG5Mb2o1aFkzSWtJcV…
CPIX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9XdWtRem96Q2pLQ1lQcE40VWtIeHJwNkx5dV8wTWh3d3d0em5wM1UzeHZRQXlvVU1TbVBhQWE2QWk3QjdyeUE?oc=5" target="_blank">CPIX</a> <font color="#6f6f6f">Finviz</font>…
Cumberland Pharmaceuticals (CPIX) Integrates Commercial Business with Apotex - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQNGd6dlQ1TUVrTG9rS0wya3pLTUk2cHNsMUlkUGYwbVNabjRGYzZtRmw1dHZpWXZ4VkFGZlAyQUJoS29jaVZQT2VoS2xpSDJLeTNkcGdwVDZLaG9oUURPVG9ldkhXSU5maGpsWHNqUk9jRVAweE1qYkVpblQ3U01yVUNhaTBfckxIcVdISH…
CPIX — Frequently Asked Questions
What is the current share price of Cumberland Pharmaceuticals Inc. (CPIX)?
As of 2026-09-19 21:16 PDT, Cumberland Pharmaceuticals Inc. (CPIX) trades at $6.62 on NasdaqGS. Its 52-week range is $1.47 to $8.97.
What is the market capitalisation of CPIX?
Cumberland Pharmaceuticals Inc. (CPIX) has a market capitalisation of $99.19M on NasdaqGS.
What is the P/E ratio of CPIX?
CPIX trades at a trailing price-to-earnings (P/E) ratio of -30.09. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.40.
What is the return on equity (ROE) of CPIX?
CPIX has a return on equity (ROE) of -14.39%. Its return on capital employed (ROCE) is -6.97%.
Is CPIX a good stock to buy?
This page provides a data-driven analysis of Cumberland Pharmaceuticals Inc. (CPIX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.